Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease
Xavier Pouwels(University of Twente), Hendrik Koffijberg(University Medical Center Utrecht), Cornelis Boersma(University Medical Center Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Marc Thelen(Radboud University Nijmegen), Marc H. Hemmelder(Nefrovisie), Ronald W. van Etten(Amphia Ziekenhuis), Dominique van Mil(University Medical Center Groningen), Marloes Langelaan(Amphia Ziekenhuis), Ron T. Gansevoort(University Medical Center Groningen), Birgitte Evers-Roeten, Lyanne M. Kieneker(University Medical Center Groningen)
Cited by 34
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
|Kidney International|2010|2.3k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
|The Lancet|2012|1.4k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k